Agonist-induced Phosphorylation of the Serotonin 5-HT2C Receptor Regulates Its Interaction with Multiple PDZ Protein 1*

Lisan L. Parker {ddagger}, Jon R. Backstrom §, Elaine Sanders-Bush {ddagger} and Bih-Hwa Shieh {ddagger} 

From the § Department of Medicine, and Center for Molecular and Cellular Neuroscience, Vanderbilt University Medical Center, Nashville, Tennessee 37232, {ddagger} Department of Pharmacology, and Center for Molecular and Cellular Neuroscience, Vanderbilt University Medical Center, Nashville, Tennessee 37232

Received for publication, October 28, 2002 , and in revised form, April 2, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Multiple PDZ domain protein 1 (MUPP1), a putative scaffolding protein containing 13 PSD-95, Dlg, ZO-1 (PDZ) domains, was identified by a yeast two-hybrid screen as a serotonin2C receptor (5-HT2C R)-interacting protein (Ullmer, C., Schmuck, K., Figge, A., and Lubbert, H. (1998) FEBS Lett. 424, 63–68). MUPP1 PDZ domain 10 (PDZ 10) associates with Ser458-Ser-Val at the carboxyl-terminal tail of the 5-HT2C R. Both Ser458 and Ser459 are phosphorylated upon serotonin stimulation of the receptor (Backstrom, J. R., Price, R. D., Reasoner, D. T., and Sanders-Bush, E. (2000) J. Biol. Chem. 275, 23620–23626). To investigate whether phosphorylation of these serines in the receptor regulates MUPP1 interaction, we used several approaches. First, we substituted the serines in the receptor carboxyl tail with aspartates to mimic phosphorylation (S458D, S459D, or S458D/S459D). Pull-down assays demonstrated that Asp mutations at Ser458 significantly decreased receptor tail interaction with PDZ 10. Next, serotonin treatment of 5-HT2C R/3T3 cells resulted in a dose-dependent reduction of receptor interaction with PDZ 10. Effects of serotonin on receptor-PDZ 10 binding could be blocked by pretreatment with a receptor antagonist. Alkaline phosphatase treatment reverses the effect of serotonin, indicating that agonist-induced phosphorylation at Ser458 resulted in a loss of MUPP1 association and also revealed a significant amount of basal phosphorylation of the receptor. We conclude that 5-HT2C R interaction with MUPP1 is dynamically regulated by phosphorylation at Ser458.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A growing number of proteins containing PDZ1 domains have been shown to play important roles in the organization and/or regulation of signaling events in cells. PDZ domains (or GLGF repeats) were named after three proteins identified over a decade ago: postsynaptic density-95, Drosophila Discs large, and zonula occludens-1 (35). These three proteins belong to the membrane-associated guanylate kinase (MAGUK) family of proteins. Most MAGUK proteins contain three PDZ domains, an Src homology 2 domain, and a guanylate kinase-like domain, each having different cellular roles. PDZ domains range from 80 to 100 amino acids in length and typically bind to the carboxyl-terminal sequence of target proteins including receptors, channels, and various signaling molecules to regulate subcellular localization, trafficking, recycling, and/or signaling (610).

MUPP1, a protein containing 13 putative PDZ domains, was isolated in a yeast two-hybrid screening for proteins that bound to the carboxyl-terminal tail of the 5-HT2C R (1). MUPP1 is expressed in many tissues, whereas the 5-HT2C R is a brain-specific protein (1, 11). The 5-HT2C R has classically been thought to couple to Gq activation; however, additional G protein families have been implicated, leading to the activation of different downstream signaling pathways including phospholipase A2, C, or D, and various cation channels (1217). Since PDZ-containing proteins can scaffold many signaling molecules together into a signal transduction complex, the interaction between MUPP1 and the 5-HT2C R was further investigated. The 5-HT2C R contains a PDZ binding motif, Ser458-Ser-Val, at its extreme carboxyl terminus, which is critical for interaction with PDZ 10 of MUPP1 (18). In an alternate approach to the yeast two-hybrid system, we independently show that PDZ 10 of MUPP1 is the primary site of interaction for the 5-HT2C R.

Serotonin stimulation has previously been shown to promote phosphorylation of the two serine residues of the 5-HT2C R PDZ binding motif, Ser458 and Ser459 (2). We therefore hypothesize that phosphorylation of the carboxyl-terminal serines of the 5-HT2C R regulates receptor interaction with MUPP1. To test this hypothesis, we investigated whether a modification of Ser458 and/or Ser459 of the 5-HT2C R carboxyl-terminal tail would alter PDZ 10 interaction. Ser458 and/or Ser459 of the receptor tail were mutated to aspartate to mimic phosphorylation (i.e. introduction of a negative charge). Next, cells expressing 5-HT2C Rs were treated with agonist or antagonist to assess the interaction of the 5-HT2C R with MUPP1. The results of these experiments support our hypothesis that phosphorylation is a key regulator of 5-HT2C R interaction with MUPP1. Furthermore, the results indicated that a significant amount of basal phosphorylation of the receptor may also play a yet undetermined role in regulating PDZ-protein interactions.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies
Polyclonal anti-peptide antibodies against amino acids 419–435 (amino acids RHTNERVARKANDPEPG) of the rat 5-HT2C R were generated as described previously (19). Anti-glutathione S-transferase (GST) antibody was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY).

DNA Constructs
Overlapping regions of MUPP1 containing two or three PDZ domains (Fig. 1), or one PDZ domain (PDZ 9, 10, or 11) were generated by reverse transcription-PCR, sequenced, and subcloned into pGEX-4T1 (Amersham Biosciences) for expression of GST fusion proteins. MUPP1 PDZ 9, 10, or 11 were also subcloned into pGEMEX-1 (Promega), a T7 gene 10 fusion protein vector. MUPP1 PDZ 9–11 was also subcloned into pcDNA3 (Invitrogen). The 5-HT2C R carboxyl-terminal tail (last 60 amino acids) with or without the PDZ binding motif (Ser458-Ser-Val) and a truncation mutant at residue 445 were subcloned into pGEMEX-1. The 5-HT2C R carboxyl-terminal tail with the PDZ binding motif was also subcloned into pGEX-4T1. The 5-HT2C R carboxyl tail Ser458-Ser-Val (WT) was modified to S458A, S458D, S459D, or S458D/S459D by PCR site-directed mutagenesis and subcloned into pGEMEX-1.



View larger version (27K):
[in this window]
[in a new window]
 
FIG. 1.
Schematic diagram of MUPP1 PDZ domains. MUPP1 has 2054 residues. Each numbered block (grey) represents the 13 individual PDZ domains of MUPP1. Pairs or individual PDZ domains were generated as GST or T7 gene 10 fusion proteins to test for 5-HT2C R interaction. Numbers under each block denote amino acid range.

 

GST Fusion Protein Overexpression
Escherichia coli was transformed with pGEX-4T1 constructs, induced to overexpress fusion proteins with isopropyl {beta}-D-thiogalactoside, and analyzed. Bacterial lysates were obtained by first adding cold lysis buffer (50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin, 1 mM benzamide, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride) to resuspend the pellets. Resuspended pellets were sonicated for 20 s on ice and centrifuged at 15,000 rpm for 30 min at 4 °C. Proteins were resolved on SDS-PAGE to confirm overexpressed GST fusion protein by Coomassie Blue staining and Western blotting using GST antibodies.

[35S] in Vitro Translation
pGEMEX-1 constructs were used for coupled transcription and translation using the TNin vitro translation system (Promega) in the presence of [35S]methionine (PerkinElmer Life Sciences) according to the supplier's protocol to generate 35S-labeled proteins.

Protein Overlay Assays
Ten micrograms of GST fusion proteins or GST were size-fractionated on SDS-PAGE and transferred onto nitrocellulose membrane. Nitrocellulose membranes were blocked with freshly prepared 1% BSA/phosphate-buffered saline for 1 h at room temperature. Solution was then replaced with 35S-labeled fusion proteins in 1% BSA/phosphate-buffered saline buffer and incubated with nitrocellulose membranes for 16 h at 4 °C. Nitrocellulose membranes were rinsed three times for 20 min at room temperature in 1% BSA/phosphate-buffered saline containing 0.2% Triton X-100. Nitrocellulose membranes were air-dried and exposed to x-ray film or a PhosphorImager screen (Amersham Biosciences) to visualize radiolabeled proteins. Western blot analysis using GST antibodies was used to document similar GST protein levels.

Cell Culture
NIH-3T3 cells stably transfected with the 5-HT2C R (5-HT2C R/3T3) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) until confluent (20). Cells were washed four times with Hanks' buffered saline solution (with Ca2+/Mg2+) and then serum starved in serum-free Dulbecco's modified Eagle's medium for 16 h. Cells were treated without or with antagonist (1 µM 2-bromolysergic acid diethylamide (BOL)) for 15 min at 37 °C prior to serotonin addition for 30 min at 37 °C. Medium was then removed, 1 ml of Tris buffer (50 mM Tris, pH 7.6, 0.5 mM EDTA, pH 8.0, 5 µM leupeptin, 1 mM phenylmethylsulfonyl fluoride) was added, and cells were scraped from plates and placed in an Eppendorf tube on ice. Membrane extracts were obtained using 300 µl of Tris buffer containing 1% Triton X-100. Membrane protein concentrations were determined by BCA protein assay (Pierce). Equal amounts of protein were added to the affinity columns. Western blot analysis using GST antibodies was used to determine that similar levels of fusion protein were pulled down.

Pull-down Assays
Twenty microliters of glutathione-Sepharose beads (Amersham Biosciences) were washed three times with PD buffer (20 mM HEPES, pH 7.6, 100 mM KCl, 10% glycerol, 0.5 mM EDTA, pH 8.0, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1% Nonidet P-40). Ten micrograms of GST fusion proteins or GST were incubated with the washed glutathione beads for 1 h at 4 °C. Five microliters of 35S-labeled fusion proteins or 50 µg of membrane extracts were added to the GST-glutathione beads and incubated for 2–3 h or overnight, respectively, at 4 °C. After incubation, GST-glutathione beads were washed six times (for assays with 35S-labeled fusion proteins) or three times (for assays with membrane extracts) with PD buffer. For pull-downs from 5-HT2C R/3T3 cell lysates, precipitated protein, containing the 5-HT2C R, was treated with peptide:N-glycanase F before SDS-PAGE (see below). Loading dye (6% SDS, 1% {beta}-mercaptoethanol, 20 mM Tris, pH 6.8, 10% glycerol plus a little bromphenol blue) was added to elute proteins. Eluates were separated on SDS-PAGE and transferred onto nitrocellulose membranes. Autoradiography or PhosphorImager screen was used to visualize radiolabeled proteins. Western blot analysis using GST and 5-HT2C R antibodies were used to document GST fusion proteins and 5-HT2C R, respectively.

Agonist Washout
After serum starvation, cells were treated with 100 nM serotonin for 30 min at 37 °C. After treatment, medium was aspirated to remove the serotonin, and cells were washed four times with Hanks' buffered saline solution. Serum-free Dulbecco's modified Eagle's medium was then added, and cells were incubated for 10 or 30 min. Cells were then lysed, and a pull-down assay was performed as mentioned above.

Band Shift Phosphorylation Assay
This assay was performed as previously described by Backstrom et al. (2). Briefly, cells grown to confluence were serum-starved and treated with increasing amounts of serotonin for 15 min at 37 °C. This incubation time was previously shown to be the minimal amount of time that would result in maximal receptor phosphorylation. Cells were then lysed, and membrane extracts containing receptors were prepared. Western blot analysis using 5-HT2C R antibodies were used to document changes in 40- and 41-kDa bands, representative of unphosphorylated and phosphorylated 5-HT2C R, respectively.

Deglycosylation
Following pull-downs from membrane extracts, beads were pelleted and washed once with PD buffer containing 0.1% SDS. Fifteen microliters of PD buffer containing 1% SDS was added to the beads, and the mixture was incubated for 15 min at 37 °C. Then 58 µl of PD buffer was added, and after mixing, 15 µl of PD buffer containing 10% Triton X-100 was added. Finally, 2 µl of peptide:N-glycanase F (Glyko or New England Biolabs) was added, and samples were incubated for 2 h at 37 °C. After deglycosylation, 15 µl of 4x loading dye were added, and samples were incubated at room temperature for 20 min prior to SDS-PAGE.

Dephosphorylation
Membrane extracts (50 µg) of untreated or serotonin-treated cells were incubated in PD buffer plus 50 units of calf intestinal (alkaline) phosphatase (New England Biolabs) for 2 h at room temperature. After incubation, pull-down assays were carried out as described above.

Western Blot Analysis
Alkaline Phosphatase Detection—Nitrocellulose membranes were blocked in 1% BSA/Tris blot buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20, 0.05% NaN3)for1hat room temperature. Membranes were then incubated with GST (1:1000 dilution) or 5-HT2C R (3–5 µg/ml) antibodies in 1% BSA/Tris blot buffer for 2 h to overnight at 4 °C. Membranes were washed three times with Tris blot buffer alone for 10 min. Alkaline phosphatase-conjugated goat anti-rabbit secondary antibodies (1:1000 dilution; Jackson Immunolaboratories) were incubated with membranes for2hat room temperature. Membranes were washed three times with Tris blot buffer and once with Tris (150 mM pH 9.4) and then developed with 5-bromo-4-chloro-3-indolyl-phosphate and nitro blue tetrazolium.

Chemilluminescence Detection—Nitrocellulose membranes were blocked in 8% milk/Tween 20 Tris buffer solution (25 mM Tris, pH 7.4, 137 mM NaCl, 0.27 mM KCl, 0.05% Tween 20) overnight at 4 °C. Membranes were then incubated with GST (1:4000 dilution) or 5-HT2C R (0.5 µg/ml) antibodies in 2% milk/Tween 20 Tris buffer solution overnight at 4 °C. Membranes were washed four times for 5 min with Tween 20 Tris buffer solution. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:20,000 dilution; Jackson Immunolaboratories) were incubated with membranes for 45 min at room temperature. Membranes were washed four times for 15 min with Tween 20 Tris buffer solution and developed with the Pierce Supersignal West Dura® kit according to the supplier's protocol. Horseradish peroxidase signal was analyzed by Bio-Rad Flouro-S, and densitometric analysis was performed by QuantityOne (Bio-Rad) software.

Statistical Analysis
All bar graph data was analyzed with Graphpad Prism one-way analysis of variance with Tukey's post-test; p < 0.05 is significant, unless otherwise noted in a figure legend. GST alone was the background control for all GST fusion protein experiments, and graph data presented are background-subtracted. Data represent the means ± S.D. from several independent experiments.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The 5-HT2C Receptor Selectively Interacts with MUPP1 PDZ 10 The carboxyl region of MUPP1 containing the last four PDZ domains (PDZ 10 to PDZ 13) was originally identified by yeast two-hybrid screening for 5-HT2C R-interacting proteins (1). However, it was unclear which PDZ domain interacted with the 5-HT2C R. Therefore, we set out to identify which domain(s) of MUPP1 interacts with the 5-HT2C R. Overlapping PDZ domain regions of MUPP1 were generated as GST fusion proteins (Fig. 1). Purified GST-MUPP1 PDZ domains were used to pull-down in vitro translated 35S-labeled 5-HT2C R carboxyl terminus fusion protein, which consists of the last 60 amino acids harboring a PDZ binding motif, Ser458-Ser-Val. Fig. 2A illustrates that significantly more receptor tail interacted with PDZ 9–11 and PDZ 9–13. A weak interaction of the receptor tail over GST alone was observed with PDZ 12 and 13, suggesting that PDZ 9–11 is the primary 5-HT2C R interacting region. In protein overlay assays, GST-MUPP1 PDZ domain fusion proteins were blotted and probed with 35S-labeled 5-HT2C R carboxyl terminus, and the 5-HT2C R tail specifically interacted with PDZ 9–11 and PDZ 9–13; no other PDZ domains displayed a significant interaction with the receptor tail (results not shown). Thus, both protein overlay and pull-down assays consistently indicate that PDZ 9–11 is responsible for interacting with the 5-HT2C R tail.



View larger version (25K):
[in this window]
[in a new window]
 
FIG. 2.
MUPP1 PDZ 10 interacts with the carboxyl terminus of the 5-HT2C R. Pull-down assays were used to determine which MUPP1 PDZ domain(s) interacted with the receptor. A, GST-MUPP1 PDZ domains bound to glutathione beads were incubated with [35S]5-HT2C R carboxyl tail. Radioactive fusion receptor tail that bound to specific PDZ domains was resolved by SDS-PAGE, transferred onto nitrocellulose, and analyzed by autoradiography or PhosphorImager. Both PDZ 9–11 and PDZ 9–13 bound significantly more radiolabeled receptor than other PDZ domains. Similar amounts of fusion proteins were used as demonstrated by Western blotting (not shown). The bar graph represents n = 6; *, p < 0.001 relative to GST. The panel above the graph is a representative pull-down result. B, the last 60 amino acids of the 5-HT2C R were used to pull down [35S]MUPP1 PDZ domain 9, 10, or 11. Radioactive PDZ domain pulled down was analyzed by autoradiography or PhosphorImager. Top panel, PDZ 10 was specifically pulled down by the 5-HT2C R carboxyl tail fusion but not by GST alone. Equal amounts of GST fusion or GST proteins were shown by Western blotting (n = 2; bottom panel).

 

To further determine the specific site of interaction, GST fusion proteins of the individual PDZ domains, 9, 10, and 11 were made (Fig. 1). Unfortunately, GST-PDZ 10 was unstable when overexpressed in bacteria. Therefore, the ability to pull down the 35S-labeled 5-HT2C R tail by GST-PDZ 9 or 11 was compared with GST-PDZ 9–11. GST fusion proteins of PDZ 9 or 11 alone were not able to bind to the receptor tail as compared with GST-PDZ 9–11, which contains PDZ 10 (data not shown). In a complementary pull-down experiment, the individual MUPP1 PDZ domains 9, 10, and 11 were in vitro translated with [35S]methionine and pulled down by the 5-HT2C R carboxyl-terminal tail expressed as a GST fusion protein (Fig. 2B). The carboxyl tail of the receptor specifically interacted with PDZ 10 and not PDZ domain 9 or 11, further supporting PDZ 10 as the interacting region for the receptor tail.

Next, we questioned whether regions upstream of the extreme carboxyl terminus of the 5-HT2C R are able to confer binding to PDZ 10. To address this question, we generated GST fusion proteins of the 5-HT2C R carboxyl-terminal tail missing only the last three residues ({Delta} PDZ) and the 5-HT2C R carboxyl-terminal tail ending at residue 445 (i.e. missing the last 15 amino acids). In an overlay assay, [35S]PDZ 9–11 was incubated with the different GST-5-HT2C R carboxyl-terminal tail fusion proteins. As illustrated in Fig. 3, PDZ 9–11 binds to WT but not the 5-HT2C R carboxyl-terminal truncation mutants.



View larger version (62K):
[in this window]
[in a new window]
 
FIG. 3.
The terminal residues of the 5-HT2C R are necessary for PDZ 10 interaction. Protein overlay assay was employed to assess what region of the carboxyl-terminal tail of the 5-HT2C R is needed for binding to MUPP1. GST fusion proteins of the 5-HT2C R carboxyl tails with the PDZ binding motif (WT), without the PDZ motif ({Delta} PDZ), and a truncated mutant at amino acid 445 (445) were separated by SDS-PAGE and transferred onto nitrocellulose blots. [35S]MUPP1 PDZ 9–11 was incubated with nitrocellulose blots, and then blots were exposed to film after the removal of nonspecific binding. MUPP1 PDZ 9–11 positively interacted with WT 5-HT2C R carboxyl tail, whereas {Delta} PDZ and 445 did not exhibit any detectable binding (top panel). A nonspecific band was observed that is also present in the GST alone lane. Western blotting was used to show the presence of fusion protein (n = 3) (bottom panel).

 

Mutation of Ser458 in the 5-HT2C Receptor Reveals Altered PDZ 10 Interaction—Studies previously demonstrated that Ser458 and Ser459 at the extreme carboxyl tail of the 5-HT2C R, the same region of the receptor necessary for PDZ 10 binding, are phosphorylated upon ligand activation (2). A function for Ser459 phosphorylation in receptor resensitization was proposed; however, the role for Ser458 phosphorylation is unknown. Based upon crystal structures of PDZ domains (2125) and data compiled on PDZ binding motifs (26), Ser458 of the 5-HT2C R is predicted to be a critical residue for interacting with PDZ 10. We therefore hypothesized that agonist-mediated phosphorylation of Ser458 disrupts the interaction of MUPP1 PDZ domain 10 and its target, the 5-HT2C R. To test this hypothesis, the serine residues in the receptor tail were replaced with aspartic acid to mimic phosphorylation. The last two serine residues of the 5-HT2C R carboxyl tail (Ser458-Ser459) were modified by PCR site-directed mutagenesis to contain S458A, S458D, S459D, or S458D/S459D substitutions. Wild-type and mutated 5-HT2C R tails were labeled with [35S]methionine and incubated with GST-PDZ 9–11. 5-HT2C R tail mutants containing S458A, S458D, and S458D/S459D substitutions displayed a marked loss of interaction to PDZ 9–11 (Fig. 4A). The S459D mutation, however, retained an ability to interact similar to wild-type interaction (Fig. 4B). These results indicate that Ser458 is an important residue in determining the interaction with PDZ 10.



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 4.
Aspartate mutation in the PDZ binding motif of the 5-HT2C R reduces MUPP1 interaction. Pull-down assays were used to determine whether mutations of serines in the 5-HT2C R carboxyl tail would affect MUPP1 PDZ 10 interaction. A, PDZ 9–11 was used to pull down [35S]5-HT2C R carboxyl tails: WT (Ser458-Ser-Val), S458A, S458D, S459D, or S458D/S459D. Mutations at Ser459 in the receptor maintained interaction comparable with wild-type interaction with PDZ 9–11, whereas mutations at Ser458 caused a significant loss of interaction. Top panel, a representative pull-down result. Bottom panel, Western blotting of the same filter to detect the amount of PDZ 9–11. B, a bar graph shows relative interaction compared with WT receptor tail. *, p < 0.001. Data were normalized to WT receptor tail, n = 6.

 

Serotonin Treatment Decreases the Ability of the 5-HT2C Receptor to Interact with PDZ 10 —Results from the 5-HT2C R tail mutants raise the possibility of a dynamic regulation of the interaction between the 5-HT2C R and MUPP1. Thus, we investigated whether agonist stimulation of the 5-HT2C R stably expressed in NIH-3T3 cells would also result in a loss of MUPP1 interaction. To determine whether serotonin stimulation had any effect on MUPP1-receptor interaction, cells were incubated with increasing amounts of serotonin, which have been shown to promote receptor phosphorylation (2). The ability of the 5-HT2C R to bind to PDZ 10 was assessed by pull-down assays. Fig. 5A shows that cells treated with serotonin led to a dose-dependent decrease in receptor interaction with MUPP1. A 50% reduction in receptor binding to PDZ 10 was observed with a concentration 100 nM serotonin. Moreover, increasing serotonin concentrations caused a dose-dependent increase in phosphorylated receptor with a concurrent decrease in the amount of unphosphorylated receptor as determined by band shift phosphorylation assays (Fig. 5B).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 5.
Serotonin treatment decreases 5-HT2C R interaction with MUPP1 in a dose-dependent manner. Serotonin treatment demonstrates a correlation between receptor interaction with MUPP1 and receptor phosphorylation state. A, membrane extracts from 5-HT2C R/3T3 cells treated with various concentrations of serotonin (1–1000 nM) were incubated with MUPP1 PDZ 9–11. 5-HT2C R bound to PDZ 9–11 was deglycosylated and analyzed by SDS-PAGE followed by Western blot analysis to determine the amount of 5-HT2C R pulled down. Amount of receptor recovered was compared and normalized to receptor from untreated cells. The bar graph represents n = 4; *, p < 0.001. B, band shift phosphorylation assay revealed a concentration-dependent decrease in levels of unphosphorylated receptor. A 40-kDa band was previously determined to be an unphosphorylated form of the receptor, and the 41-kDa band was the phosphorylated form. Changes in mobility of the receptor from the 40- to 41-kDa band were compared and quantitated after increasing amounts of serotonin treatment. Data were normalized to the 40-kDa (unphosphorylated) receptor band from untreated cells. The bar graph represents n = 3; *, p < 0.01; **, p < 0.001.

 

To determine whether the loss of PDZ 10 interaction with the receptor was a consequence of agonist binding with 5-HT2C Rs, cells were preincubated in the absence or presence 1 µM of BOL, a 5-HT2C R antagonist, for 15 min prior to the addition of serotonin. BOL antagonized a subsequent serotonin-mediated decrease in receptor pull-down (Fig. 6), thereby demonstrating that the loss of PDZ 10 interaction is a direct consequence of receptor activation. BOL alone had no effect.



View larger version (25K):
[in this window]
[in a new window]
 
FIG. 6.
Serotonin effects can be modulated by 5-HT2C R antagonist treatment. Pull-down assays from 5-HT2C R/3T3 cells show that receptor interaction with MUPP1 can be modulated by BOL. Membrane lysates from untreated cells or cells treated with 100 nM serotonin in the absence or presence of antagonist (1 µM BOL) were incubated with PDZ 9–11. BOL blocks the effects of 100 nM serotonin on 5-HT2C R binding to PDZ 9–11, whereas BOL alone has no effects. Chemiluminescence using a 5-HT2C R-specific antibody was used to compare the amount of receptor protein pulled down. The amount of receptor pulled down was normalized to untreated receptor lysate (control); n = 6; *, p < 0.01. The panel above the bar graph is a representative experiment.

 

Alkaline Phosphatase Treatment of the 5-HT2C Receptor Increases PDZ 10 Interaction and Reveals 5-HT2C Receptor Basal Phosphorylation—The reduction of 5-HT2C R binding to MUPP1 may be the direct result of receptor phosphorylation. We therefore investigated whether treatment of lysate containing receptor with alkaline phosphatase would restore MUPP1 interaction. Cells were treated with agonist, and cell lysates were incubated with alkaline phosphatase prior to pull-down assays. As shown in Fig. 7A, alkaline phosphatase treatment resulted in more receptor pull-down in serotonin-stimulated cells. In the absence of serotonin, alkaline phosphatase treatment doubled the amount of receptor binding to PDZ 10 compared with untreated cells. These findings directly support a role for agonist-induced phosphorylation in disrupting 5-HT2C R binding to MUPP1 as well as uncover a potential function for previously reported basal phosphorylation of the receptor.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 7.
Phosphatase and agonist washout restore 5-HT2C receptor interaction with PDZ 10. A, membrane lysate from cells treated without or with agonist (100 nM serotonin) was incubated with 1000 units/mg of protein of alkaline phosphatase and then incubated with PDZ 9–11. Alkaline phosphatase treatment resulted in an increase in the amount of receptor pulled down from extracts prepared from untreated and serotonin-treated cells. B, the effect of agonist washout (10 or 30 min) following 100 nM serotonin treatment was investigated. Membrane lysates from these cells were incubated with PDZ 9–11. A time-dependent increase of the MUPP1 interaction following serotonin washout was observed. For both graphs, the amount of receptor pulled down was normalized to untreated receptor lysate (control); n = 6 or 3, respectively; *, p < 0.001; **, p < 0.01; ***, p < 0.05. The panels above the bar graphs are representative experiments.

 

Phosphorylation of the receptor is reversible; therefore, we investigated the activity of endogenous phosphatases against the receptor by washout experiments. Cells were treated with agonist and then washed thoroughly and incubated in serum-free medium for 10 or 30 min before lysis and pull-down assay. Fig. 7B demonstrates a time-dependent increase in 5-HT2C R binding to MUPP1 (Fig. 7B). These results are consistent with previously published data indicating a time-dependent dephosphorylation of the receptor (2).


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
5-HT2C Rs are implicated in physiological processes such as cerebrospinal fluid production as well as illnesses and disorders including anxiety, migraines, and eating and sleeping disorders (27, 28). Furthermore, the 5-HT2C R is a target for hallucinogenic drugs such as lysergic acid diethylamide (29, 30). A thorough understanding of intracellular signaling by the 5-HT2C R, including its interaction with PDZ domain containing proteins, may give insight into the cellular mechanisms that underlie these diverse physiological processes. PDZ domain-containing proteins are involved in the localization of potassium channels and glutamate receptors in the synapse as well as localization of numerous other receptors and proteins (3136). PDZ domains typically bind to the carboxyl termini of target proteins that contain a PDZ binding motif. Interestingly, some PDZ binding motifs have been shown to be phosphorylated (3747), including the 5-HT2C R (2).

In the current paper, 5-HT2C R interaction with PDZ 10 of MUPP1 was independently confirmed by using pull-down and protein overlay assays. These results are consistent with the report by Becamel et al. (18) that demonstrated PDZ 10 interaction with the 5-HT2C R in yeast two-hybrid assays. Becamel et al. (18) also demonstrated that mutation of the critical residues of the PDZ motif on the receptor, Ser458 or Val460 to alanine, abolished interaction with PDZ 10. Similarly, our results also document that the carboxyl-terminal residues of the 5-HT2C R are necessary for MUPP1 interaction; truncated 5-HT2C R tail proteins missing the terminal PDZ binding motif failed to show detectable interaction with MUPP1. There are four recognized classes of carboxyl-terminal PDZ binding motifs to date (48). The carboxyl terminus of the 5-HT2C R belongs to a type 1 PDZ binding motif (X-Ser/Thr-X-Val/Ile/Leu-COOH). Ser458 of the 5-HT2C R is predicted to be a critical residue for interacting with the PDZ 10 domain backbone. Since both Ser458 and Ser459 of the 5-HT2C R are phosphorylated upon ligand activation (2), we examined the role of receptor phosphorylation on the 5-HT2C R-MUPP1 interaction.

In the next series of experiments, we investigated whether mutations of the terminal serines to aspartates that mimic phosphorylation of serines would affect binding of the 5-HT2C R to PDZ 10 of MUPP1. S458D and S458D/S459D mutations led to a significant loss of receptor tail interaction to PDZ 10. These data are in agreement with crystal structure data indicating that the hydroxyl group of the Ser at the –2 position of a type I PDZ binding target is important for hydrogen bonding to His at the first position of the {alpha} B helix ({alpha} B1) of a type I PDZ domain such as PDZ 10 (21). Our data suggest that the introduction of a negatively charged group at the –2 position of the receptor tail disrupts the hydrogen bonding to the PDZ 10 domain resulting in a loss of interaction. The S459D mutation, on the other hand, retains wild-type interaction. This result is also consistent with structural studies showing that the side chain of the –1 position residue of a PDZ binding target does not hydrogen-bond to residues in the PDZ domain backbone but rather points away from the pocket (21). Interestingly, c-Kit, a receptor tyrosine kinase whose carboxyl-terminal sequence ends in Asp-Asp-Val, and claudin-1, a tight junction protein whose carboxyl-terminal sequence ends in Asp-Tyr-Val, have been identified to interact with PDZ 10 of MUPP1 (49, 50). These observations are unexpected in light of structural information on PDZ-ligand complexes, including the current data of carboxyl-terminal mutants in the 5-HT2C receptor. One possible explanation is that c-Kit and claudin-1 interaction with PDZ 10 may involve additional residues upstream from the carboxyl termini.

To determine whether serotonin stimulation within a cellular context would alter 5-HT2C R binding to PDZ 10, we examined the receptor stably expressed in NIH-3T3 cells in the absence or presence of serotonin. A dose-dependent loss of interaction of the receptor with MUPP1 occurred when receptor was incubated with increasing concentrations of serotonin. Furthermore, this concentration curve parallels serotonin-induced receptor phosphorylation, suggesting that a change in receptor phosphorylation state regulates binding to MUPP1 PDZ 10. The effect of serotonin was blocked by the 5-HT2C R antagonist, BOL. Moreover, alkaline phosphatase treatment reversed the effect of serotonin. Interestingly, in the absence of serotonin, phosphatase treatment also resulted in increased receptor binding to PDZ 10. We speculate that this may be indicative of constitutive phosphorylation; basal phosphorylation for this receptor was previously observed by Westphal et al. (51) when cells were metabolically labeled with [32P]orthophosphoric acid. Alternatively, an unidentified protein that attenuates MUPP1 binding to the receptor may be reduced by phosphatase treatment and account for this observation. When receptor was stimulated with a maximal serotonin-mediated receptor phosphorylation dose, agonist washout experiments demonstrated that receptor interaction with MUPP1 was restored in a time-dependent manner. We speculate that this restored binding between the receptor and MUPP1 is the result of endogenous phosphatases. Results from antagonist, phosphatase treatments, and agonist washout experiments demonstrated the specificity of our analyses and support the hypothesis that phosphorylation regulates the interaction of 5-HT2C R with MUPP1. A thorough investigation of the kinase responsible for phosphorylation of the 5-HT2C R has been initiated. Initial studies suggest that the usual second messenger-activated kinases are not involved (data not shown). This finding is consistent with investigations of another G-protein-coupled receptors, the {beta}-adrenergic receptors, which have identified GRK2 and GRK5 as the major kinases responsible for phosphorylating receptor carboxyl threonine and serine residues (40, 52, 53).

Regulation of PDZ-protein interactions by phosphorylation is emerging as an important modulator of cellular signaling. Phosphorylation regulation of a PDZ domain interaction was first observed in the potassium channel Kir 2.3 (37). Protein kinase A phosphorylation of Kir 2.3 causes a disruption of its interaction with PSD-95. Protein kinase A also regulates the interaction between Kir 2.2, another potassium channel, and synapse-associated protein 97, SAP97, resulting in a decreased interaction (38). G protein-coupled receptor kinases have been shown to phosphorylate the {beta}1- and {beta}2-adrenergic receptors at carboxyl-terminal serines of a PDZ binding motif, which reduces their interaction with PDZ domain proteins (39, 40, 54). The {alpha}-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA)glutamate receptor exhibits dual specificity for its interacting partners PICK1 (protein interacting with C kinase) and GRIP/ABP (glutamate receptor-interacting protein)/(AMPA receptor-binding protein), depending upon whether the glutamate receptor 2/3 subunit is phosphorylated by protein kinase C (4245, 55, 56). Finally, the binding of stargazin, a transmembrane protein that associates with AMPA receptors, to PSD-95 is regulated by protein kinase A phosphorylation (46, 47, 57, 58).

In this paper, we established that phosphorylation of the 5-HT2C R at Ser458, the serine residue critical for binding to PDZ 10, resulted in a decrease in MUPP1 interaction. We also provide evidence that receptor interaction with MUPP1 is sensitive to basal phosphorylation of the receptor. Due to the assembling nature of PDZ proteins, we propose that MUPP1 regulates the coupling of the 5-HT2C R to various effectors to activate downstream signaling processes. MUPP1 interaction with the 5-HT2C R when the receptor is in an unphosphorylated form may keep the receptor in a conformation state (and vice versa) that is masked from some of its downstream signaling partners. Then in an agonist-dependent or -independent manner (an event that is not fully understood), the receptor becomes phosphorylated at the PDZ binding motif, and MUPP1 is released from the receptor, resulting in a change in conformation that reveals downstream signaling molecules scaffolded to MUPP1. Changes in MUPP1 folding have been postulated as a result of observations by Becamel et al. (18), showing that when MUPP1 is expressed alone in COS cells, a carboxyl-terminal vesicular stomatitis virus epitope tag is not accessible; however, when MUPP1 is co-expressed with the 5-HT2C R, the tag is accessible. The possibility also exists that the sole function of MUPP1 may be to simply traffic or anchor the 5-HT2C R to specific membrane domains without a direct effect upon receptor signaling. Based upon the data presented here and previous studies on PDZ proteins and receptors, phosphorylation appears to be a critical regulator of PDZ protein-protein interactions, including regulation of the interaction between MUPP1 and the 5-HT2C R. Our results suggest that cells may have an underlying mechanism to dynamically regulate overall cellular activity in the absence and subsequent exposure to agonist by modulating basal receptor phosphorylation and thereby balancing the extent of maximal receptor activation.


    FOOTNOTES
 
* This work was supported by National Institutes of Health (NIH) Grants EY09743 (to B.-H. S.) and MH34007 (to E. S.-B.), a grant from the National Alliance for Research on Schizophrenia and Depression (to J. R. B.), and NIGMS, NIH Minority Access to Research Careers pre-doctoral fellowship F31 GM20275 (to L. L. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: 402 Robinson Research Bldg., Vanderbilt University Medical Center, 23rd Ave. at Pierce, Nashville, TN 37232. Tel.: 615-343-0441; Fax: 615-343-6532; E-mail: Bih-Hwa.Shieh{at}vanderbilt.edu.

1 The abbreviations used are: PDZ, postsynaptic density-95, Discs large, zonula occludens-1; MUPP1, multiple PDZ domain protein 1; 5-HT2C R, serotonin2C receptor; MAGUK, membrane-associated guanylate kinase; GST, glutathione S-transferase; BOL, 2-bromo-lysergic acid diethylamide; AMPA, {alpha}-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate; WT, wild type. Back


    ACKNOWLEDGMENTS
 
We thank Drs. Brian Wadzinski and Vsevolod Gurevich for discussions related to phosphatases and kinases. We thank Drs. Mike S. S. Chang and Raymond D. Price for critical review and comments on this manuscript. We also thank Blairanne Williams, Kathleen Rutledge, and Kenyatta Thompson for excellent technical assistance with cell culture.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ullmer, C., Schmuck, K., Figge, A., and Lubbert, H. (1998) FEBS Lett. 424, 63–68[CrossRef][Medline] [Order article via Infotrieve]
  2. Backstrom, J. R., Price, R. D., Reasoner, D. T., and Sanders-Bush, E. (2000) J. Biol. Chem. 275, 23620–23626[Abstract/Free Full Text]
  3. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1992) Neuron 9, 929–942[Medline] [Order article via Infotrieve]
  4. Woods, D. F., and Bryant, P. J. (1991) Cell 66, 451–464[Medline] [Order article via Infotrieve]
  5. Stevenson, B. R., Siliciano, J. D., Mooseker, M. S., and Goodenough, D. A. (1986) J. Cell Biol. 103, 755–766[Abstract]
  6. Sheng, M., and Sala, C. (2001) Annu. Rev. Neurosci. 24, 1–29[CrossRef][Medline] [Order article via Infotrieve]
  7. Hung, A. Y., and Sheng, M. (2002) J. Biol. Chem. 277, 5699–5702[Free Full Text]
  8. Huber, A. (2001) Eur. J. Neurosci. 14, 769–776[CrossRef][Medline] [Order article via Infotrieve]
  9. Fanning, A. S., and Anderson, J. M. (1998) Curr. Top. Microbiol. Immunol. 228, 209–233[Medline] [Order article via Infotrieve]
  10. Kornau, H. C., Seeburg, P. H., and Kennedy, M. B. (1997) Curr. Opin. Neurobiol. 7, 368–373[CrossRef][Medline] [Order article via Infotrieve]
  11. Julius, D., MacDermott, A. B., Axel, R., and Jessell, T. M. (1988) Science 241, 558–564[Medline] [Order article via Infotrieve]
  12. Conn, P. J., and Sanders-Bush, E. (1986) J. Neurochem. 47, 1754–1760[Medline] [Order article via Infotrieve]
  13. Mayer, S. E., and Sanders-Bush, E. (1994) Mol. Pharmacol. 45, 991–996[Abstract]
  14. Kaufman, M. J., Hartig, P. R., and Hoffman, B. J. (1995) J. Neurochem. 64, 199–205[Medline] [Order article via Infotrieve]
  15. Chang, M., Zhang, L., Tam, J. P., and Sanders-Bush, E. (2000) J. Biol. Chem. 275, 7021–7029[Abstract/Free Full Text]
  16. Price, R. D., Weiner, D. M., Chang, M. S., and Sanders-Bush, E. (2001) J. Biol. Chem. 276, 44663–44668[Abstract/Free Full Text]
  17. McGrew, L., Chang, M. S., and Sanders-Bush, E. (2002) Mol. Pharmacol. 62, 1339–1343[Abstract/Free Full Text]
  18. Becamel, C., Figge, A., Poliak, S., Dumuis, A., Peles, E., Bockaert, J., Lubbert, H., and Ullmer, C. (2001) J. Biol. Chem. 276, 12974–12982[Abstract/Free Full Text]
  19. Backstrom, J. R., and Sanders-Bush, E. (1997) J. Neurosci. Methods 77, 109–117[CrossRef][Medline] [Order article via Infotrieve]
  20. Barker, E. L., and Sanders-Bush, E. (1993) Mol. Pharmacol. 44, 725–730[Abstract]
  21. Doyle, D. A., Lee, A., Lewis, J., Kim, E., Sheng, M., and MacKinnon, R. (1996) Cell 85, 1067–1076[Medline] [Order article via Infotrieve]
  22. Daniels, D. L., Cohen, A. R., Anderson, J. M., and Brunger, A. T. (1998) Nat. Struct. Biol. 5, 317–325[Medline] [Order article via Infotrieve]
  23. Karthikeyan, S., Leung, T., Birrane, G., Webster, G., and Ladias, J. A. (2001) J. Mol. Biol. 308, 963–973[CrossRef][Medline] [Order article via Infotrieve]
  24. Morais Cabral, J. H., Petosa, C., Sutcliffe, M. J., Raza, S., Byron, O., Poy, F., Marfatia, S. M., Chishti, A. H., and Liddington, R. C. (1996) Nature 382, 649–652[CrossRef][Medline] [Order article via Infotrieve]
  25. Tochio, H., Hung, F., Li, M., Bredt, D. S., and Zhang, M. (2000) J. Mol. Biol. 295, 225–237[CrossRef][Medline] [Order article via Infotrieve]
  26. Songyang, Z., Fanning, A. S., Fu, C., Xu, J., Marfatia, S. M., Chishti, A. H., Crompton, A., Chan, A. C., Anderson, J. M., and Cantley, L. C. (1997) Science 275, 73–77[Abstract/Free Full Text]
  27. Roth, B. L., Willins, D. L., Kristiansen, K., and Kroeze, W. K. (1998) Pharmacol. Ther. 79, 231–257[CrossRef][Medline] [Order article via Infotrieve]
  28. De Vry, J., and Schreiber, R. (2000) Neurosci. Biobehav. Rev. 24, 341–353[CrossRef][Medline] [Order article via Infotrieve]
  29. Burris, K. D., Breeding, M., and Sanders-Bush, E. (1991) J. Pharmacol. Exp. Ther. 258, 891–896[Abstract]
  30. Fiorella, D., Helsley, S., Lorrain, D. S., Rabin, R. A., and Winter, J. C. (1995) Psychopharmacology 121, 364–372[Medline] [Order article via Infotrieve]
  31. Shieh, B. H., and Zhu, M. Y. (1996) Neuron 16, 991–998[Medline] [Order article via Infotrieve]
  32. Shieh, B. H., Zhu, M. Y., Lee, J. K., Kelly, I. M., and Bahiraei, F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12682–12687[Abstract/Free Full Text]
  33. Adamski, F. M., Zhu, M. Y., Bahiraei, F., and Shieh, B. H. (1998) J. Biol. Chem. 273, 17713–17719[Abstract/Free Full Text]
  34. Tsunoda, S., Sierralta, J., Sun, Y., Bodner, R., Suzuki, E., Becker, A., Socolich, M., and Zuker, C. S. (1997) Nature 388, 243–249[CrossRef][Medline] [Order article via Infotrieve]
  35. Scott, K., and Zuker, C. S. (1998) Nature 395, 805–808[CrossRef][Medline] [Order article via Infotrieve]
  36. Tsunoda, S., and Zuker, C. S. (1999) Cell Calcium 26, 165–171[CrossRef][Medline] [Order article via Infotrieve]
  37. Cohen, N. A., Brenman, J. E., Snyder, S. H., and Bredt, D. S. (1996) Neuron 17, 759–767[Medline] [Order article via Infotrieve]
  38. Leonoudakis, D., Mailliard, W., Wingerd, K., Clegg, D., and Vandenberg, C. (2001) J. Cell Sci. 114, 987–998[Abstract/Free Full Text]
  39. Cao, T. T., Deacon, H. W., Reczek, D., Bretscher, A., and von Zastrow, M. (1999) Nature 401, 286–290[CrossRef][Medline] [Order article via Infotrieve]
  40. Hu, L. A., Chen, W., Premont, R. T., Cong, M., and Lefkowitz, R. J. (2002) J. Biol. Chem. 277, 1607–1613[Abstract/Free Full Text]
  41. Hall, R. A., Spurney, R. F., Premont, R. T., Rahman, N., Blitzer, J. T., Pitcher, J. A., and Lefkowitz, R. J. (1999) J. Biol. Chem. 274, 24328–24334[Abstract/Free Full Text]
  42. Matsuda, S., Mikawa, S., and Hirai, H. (1999) J. Neurochem. 73, 1765–1768[CrossRef][Medline] [Order article via Infotrieve]
  43. Dev, K. K., Nakajima, Y., Kitano, J., Braithwaite, S. P., Henley, J. M., and Nakanishi, S. (2000) J. Neurosci. 20, 7252–7257[Abstract/Free Full Text]
  44. Chung, H. J., Xia, J., Scannevin, R. H., Zhang, X., and Huganir, R. L. (2000) J. Neurosci. 20, 7258–7267[Abstract/Free Full Text]
  45. Xia, J., Chung, H. J., Wihler, C., Huganir, R. L., and Linden, D. J. (2000) Neuron 28, 499–510[Medline] [Order article via Infotrieve]
  46. Choi, J., Ko, J., Park, E., Lee, J. R., Yoon, J., Lim, S., and Kim, E. (2002) J. Biol. Chem. 277, 12359–12363[Abstract/Free Full Text]
  47. Chetkovich, D. M., Chen, L., Stocker, T. J., Nicoll, R. A., and Bredt, D. S. (2002) J. Neurosci. 22, 5791–5796[Abstract/Free Full Text]
  48. Vaccaro, P., Brannetti, B., Montecchi-Palazzi, L., Philipp, S., Citterich, M. H., Cesareni, G., and Dente, L. (2001) J. Biol. Chem. 276, 42122–42130[Abstract/Free Full Text]
  49. Mancini, A., Koch, A., Stefan, M., Niemann, H., and Tamura, T. (2000) FEBS Lett. 482, 54–58[CrossRef][Medline] [Order article via Infotrieve]
  50. Hamazaki, Y., Itoh, M., Sasaki, H., Furuse, M., and Tsukita, S. (2002) J. Biol. Chem. 277, 455–461[Abstract/Free Full Text]
  51. Westphal, R. S., Backstrom, J. R., and Sanders-Bush, E. (1995) Mol. Pharmacol. 48, 200–205[Abstract]
  52. Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13796–13803[Abstract/Free Full Text]
  53. Seibold, A., January, B. G., Friedman, J., Hipkin, R. W., and Clark, R. B. (1998) J. Biol. Chem. 273, 7637–7642[Abstract/Free Full Text]
  54. Hall, R. A., Premont, R. T., Chow, C. W., Blitzer, J. T., Pitcher, J. A., Claing, A., Stoffel, R. H., Barak, L. S., Shenolikar, S., Weinman, E. J., Grinstein, S., and Lefkowitz, R. J. (1998) Nature 392, 626–630[CrossRef][Medline] [Order article via Infotrieve]
  55. Daw, M. I., Chittajallu, R., Bortolotto, Z. A., Dev, K. K., Duprat, F., Henley, J. M., Collingridge, G. L., and Isaac, J. T. (2000) Neuron 28, 873–886[Medline] [Order article via Infotrieve]
  56. Kim, C. H., Chung, H. J., Lee, H. K., and Huganir, R. L. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11725–11730[Abstract/Free Full Text]
  57. Chen, L., Chetkovich, D. M., Petralia, R. S., Sweeney, N. T., Kawasaki, Y., Wenthold, R. J., Bredt, D. S., and Nicoll, R. A. (2000) Nature 408, 936–943[CrossRef][Medline] [Order article via Infotrieve]
  58. Schnell, E., Sizemore, M., Karimzadegan, S., Chen, L., Bredt, D. S., and Nicoll, R. A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 13902–13907[Abstract/Free Full Text]